Shanghai Juncell Therapeutics
Clinical trials sponsored by Shanghai Juncell Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could your own tumor cells beat melanoma? new trial tests immune cell therapy Results expected Sep 2026 (estimated)
- Engineered immune cells take on tough gynecologic tumors Results expected Sep 2026 (estimated)
- Can a Patient's own immune cells fight tough cancers? Results expected Sep 2026 (estimated)
- Engineered immune cells take on advanced cancers in early trial Results expected Nov 2026 (estimated)
- Engineered immune cells take on Hard-to-Treat cancers Results expected Nov 2026 (estimated)
-
Could your own immune cells beat advanced melanoma?
Disease control CompletedThis trial tested a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The study enrolled 18 partici…
Phase 1/2 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Supercharged immune cells take on tough gynecologic cancers
Disease control CompletedThis early study tested a new therapy called GC203 TIL in 26 people with advanced gynecologic tumors that had stopped responding to standard treatments. Doctors took immune cells from each patient's tumor, genetically modified them to be more powerful, and infused them back. The …
Early phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Your own tumor cells could be the key to fighting cancer
Disease control CompletedThis early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…
Phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC